Literature DB >> 18655127

Spina bifida before and after folic acid fortification in Canada.

Philippe De Wals1, Fassiatou Tairou, Margot I Van Allen, R Brian Lowry, Jane A Evans, Michiel C Van den Hof, Marian Crowley, Soo-Hong Uh, Pamela Zimmer, Barbara Sibbald, Bridget Fernandez, Nora S Lee, Theophile Niyonsenga.   

Abstract

BACKGROUND: In 1998, fortification of a large variety of cereal products with folic acid became mandatory in Canada. A multicentric study was carried out to assess the impact of this policy on the frequency of NTDs. The present analysis focused on spina bifida.
METHODS: The study population included approximately 2 million livebirths, stillbirths, and terminations of pregnancies because of fetal anomalies among women residing in seven Canadian provinces, from 1993 to 2002. Spina bifida cases were divided according to the upper limit of the defect: upper (cranial, cervical, or thoracic) and lower (lumbar or sacral) defects. Based on published results of red blood cell folate tests, the study period was divided into prefortification, partial fortification, and full fortification periods.
RESULTS: A total of 1,286 spina bifida cases were identified: 51% livebirths, 3% stillbirths, and 46% terminations. Prevalence decreased from 0.86/1,000 in the prefortification to 0.40 in the full fortification period, while the proportion of upper defects decreased from 32% to 13%. Following fortification, regional variations in the prevalence and distribution of sites almost disappeared.
CONCLUSIONS: Results confirmed the etiologic heterogeneity of spina bifida and the more pronounced effect of folic acid in decreasing the risk of the more severe clinical presentations. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18655127     DOI: 10.1002/bdra.20485

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  20 in total

Review 1.  Folic acid and orofacial clefts: a review of the evidence.

Authors:  G L Wehby; J C Murray
Journal:  Oral Dis       Date:  2010-01       Impact factor: 3.511

2.  A description of spina bifida cases and co-occurring malformations, 1976-2011.

Authors:  Samantha E Parker; Mahsa M Yazdy; Allen A Mitchell; Laurie A Demmer; Martha M Werler
Journal:  Am J Med Genet A       Date:  2013-12-19       Impact factor: 2.802

Review 3.  In utero intervention for urologic diseases.

Authors:  Douglass B Clayton; John W Brock
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

4.  Red Blood Cell Folate Insufficiency among nonpregnant Women of Childbearing age in Guatemala 2009 to 2010: Prevalence and predicted Neural Tube Defects risk.

Authors:  Jorge Rosenthal; Mary-Elizabeth Reeve; Nicte Ramirez; Krista S Crider; Joe Sniezek; Claudia Vellozzi; Owen Devine; Eunice Lopez-Pazos
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-03-24

5.  Trends in incidence and long-term outcomes of myelomeningocele in British Columbia.

Authors:  Taylor North; Alexander Cheong; Paul Steinbok; Julia Ae Radic
Journal:  Childs Nerv Syst       Date:  2017-12-13       Impact factor: 1.475

6.  Folate status of the population in the Canadian Health Measures Survey.

Authors:  Cynthia K Colapinto; Deborah L O'Connor; Mark S Tremblay
Journal:  CMAJ       Date:  2010-12-13       Impact factor: 8.262

7.  Folic Acid Fortification and Women's Folate Levels in Selected Communities in Brazil - A First Look.

Authors:  Hrishikesh Chakraborty; Kwame A Nyarko; Norman Goco; Janet Moore; Danilo Moretti-Ferreira; Jeffrey C Murray; George L Wehby
Journal:  Int J Vitam Nutr Res       Date:  2014       Impact factor: 1.784

8.  The association between urinary continence and quality of life in paediatric patients with spina bifida and tethered cord.

Authors:  Jamie D Olesen; Darcie A Kiddoo; Peter D Metcalfe
Journal:  Paediatr Child Health       Date:  2013-08       Impact factor: 2.253

9.  Modeling the impact of folic acid fortification and supplementation on red blood cell folate concentrations and predicted neural tube defect risk in the United States: have we reached optimal prevention?

Authors:  Krista S Crider; Yan Ping Qi; Owen Devine; Sarah C Tinker; Robert J Berry
Journal:  Am J Clin Nutr       Date:  2018-06-01       Impact factor: 7.045

10.  Retrospective Assessment of Cost Savings From Prevention: Folic Acid Fortification and Spina Bifida in the U.S.

Authors:  Scott D Grosse; Robert J Berry; J Mick Tilford; James E Kucik; Norman J Waitzman
Journal:  Am J Prev Med       Date:  2016-01-11       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.